Akynzeo 300 mg/0.5 mg hard capsules
Sponsors
K-Group Beta Inc., Fondazione IRCCS Istituto Nazionale Dei Tumori, Karyopharm Therapeutics Inc.
Conditions
Endometrial cancerFallopian TubeHigh-Grade Serous OvarianTreatment naïve patients with MFor Primary Peritoneal Cancerrecurrent or persistent uterine serous carcinoma
Phase 2
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RecruitingCTIS2022-502983-19-00
Start: 2025-07-31Target: 137Updated: 2026-01-22
A Phase 2 Open-label, multicenter study to evaluate efficacy and safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma
CompletedCTIS2023-507324-23-00
Start: 2024-05-22End: 2025-10-23Target: 70Updated: 2024-04-11
Phase 3
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
Active, not recruitingCTIS2023-506139-13-00
Start: 2024-01-04Target: 195Updated: 2025-10-09
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Not yet recruitingCTIS2025-524641-27-00
Target: 50Updated: 2026-08-21